Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT07568275
Phase
EARLY_PHASE1
Status
Active Not Recruiting

Conditions

  • Acute Kidney Injury
  • Cirrhosis
  • Septic Shock
  • Vasodilatory Shock

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Giapreza — DRUG
    2.5 mg/mL

Study Details

A study to see whether a medication called Angiotensin II works better than the routinely used medication to raise blood pressure in people with liver disease who are experiencing a serious drop in blood pressure. The investigators want to find out if Angiotensin II can help the heart and blood vessels work together more effectively than standard treatments.

Key Dates

Start date
Nov 15, 2024
Status verified
Feb 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2028

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Angiotensin II
    Angiotensin II will be continued for 24 hours and then discontinued, and SOC vasopressors resumed according to institutional practices.
  • No Intervention: Standard of Care
    Fixed-dose vasopressin and standard of care vasopressors increased as per institutional guidelines according to MAP targets.

Primary Outcome Measure

Change in arterial elastance [ Time Frame: 6 hours ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Cleveland ClinicClevelandOhio44195-

Find similar trials in Cleveland, OH

By research site
The Cleveland Clinic· Cleveland, OH

Related Studies